A retrospective study of Pembrolizumab or Nivolumab in elderly patients with Hodgkin's lymphoma
Latest Information Update: 29 Nov 2019
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
Most Recent Events
- 29 Nov 2019 New trial record
- 06 Nov 2019 Results released in 61st Annual Meeting and Exposition of the American Society of Hematology.